Vimarsana
Biggest News Aggregation in the World

David Jaffray News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from David Jaffray. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In David Jaffray Today - Breaking & Trending Today

CNBC Squawk On The Street May 18, 2015 - Vimarsana News

CNBC Squawk On The Street May 18, 2015

Today a pair of deals. Endo buying parr pharmaceutical and for just over 2 billion. And potentially a third in the making i can confirm that they have resumed talks around a possible deal. Well have more timely to help, tim cook tells graduates not to live lives on the sidelines while apple acquires a gps startup. The dow and s p just shy of new alltime intraday highs. The dow, as we said about 16 points away from record territory. People wonder if this is the breakout of the wedge weve been watching for so long jim. Its certainly possible. We saw things last week that were really kind of very...

46 chief digital officers to know - Vimarsana News

46 chief digital officers to know

Becker's is delighted to name 46 hospital and health system chief digital officers to know. 

Scammers Targeting Patients With Cancer - Vimarsana News

Scammers Targeting Patients With Cancer

Some patients are forced to deal with “infuriating” attempts at exploitation while navigating their disease.

MD Anderson launches $100M data science institute - Vimarsana News

MD Anderson launches $100M data science institute

MD Anderson Cancer Center has launched a $100 million data science institute to advance oncology treatment, research and patient experience.

Break Through Cancer funds AML research at MD Anderson - Vimarsana News

Break Through Cancer funds AML research at MD Anderson

The University of Texas MD Anderson Cancer Center was awarded more than $5.7 million in grants from Break Through Cancer to support collaborative research teams working to discover novel molecular targets to eradicate minimal residual disease in acute myeloid leukemia (AML) and to treat clonal hematopoiesis, a precursor to AML.